Method of inhibiting nonsense-mediated mRNA decay
View Patent ↗Provided are methods for treating a NAD comprising administering to a patient suffering from a NAD a composition comprising an eIF5A inhibitor compound in an amount effective to prevent intracellular hypusination of eIF5A, whereby gene expression of NMD-susceptible mRNA is increased.
1. A method of determining a presence of a nonsense mutation in a protein of a patient, the method comprising:
a. obtaining a cell sample from the patient, wherein said cell sample comprises cells expressing mRNA-containing premature stop codon;
b. culturing said sample in the presence of an inhibitor of eIF5A to generate mRNA encoding said protein;
c. extracting mRNA;
d. obtaining complementary DNA (cDNA) from the mRNA encoding said protein; and
e. analyzing the sequence of said cDNA, wherein said inhibitor is selected from the group consisting of:
a. compound of formula (I):
wherein
R 1 is (C 1 -C 6 ) alkyl;
R 2 is (C 1 -C 10 ) straight or branched alkyl, (C 3 -C 6 )cycloalkyl or phenoxy(C 1 -C 3 )alkyl, where the phenoxy group is substituted by substituted or unsubstituted phenoxy; and
R 3 is hydrogen or a pharmacologically acceptable salt;
b. a compound of formula (II):
wherein
R 1 is hydrogen or a pharmacologically acceptable salt;
R 2 is ortho hydroxyl-substituted phenyl ot pyridyl, where the phenyl or pyridyl group is otherwise unsubstituted or substituted with 1 to 3 additional substituents selected from the group consisting of (C 1 -C 6 ) alkyl, phenyl, (C 1 -C 6 ), alkoxy, halogen, or hydroxyl;
A-B is —CH 2 —CR 3 — or —CH═CH—; and R 3 is hydrogen or (C 1 -C 6 )alkyl;
c) a compound of formula (III) or (IV);
wherein R 1 , R 2 , R 3 , and R 4 each individually represent a hydrogen, an alkyl, alkenyl, or alkoxy group containing 1 to about 8 carbon atoms, an aryl, arylaklyl, or cycloalkyl group containing about 5 to 12 carbon atoms, or a peptide or peptidomimetic moiety containing 10 to about 30 carbon atoms.
2. A method of determining a presence of a nonsense mutation in a protein of a patient, the method comprising:
a. obtaining a cell sample from the patient, wherein said cell sample comprises cells expressing mRNA-containing premature stop codon;
b. culturing said sample in the presence of an inhibitor of eIF5A to generate mRNA encoding said protein;
c. extracting mRNA;
d. obtaining complementary DNA (cDNA) from the mRNA encoding said protein; and
e. analyzing the sequence of said cDNA, wherein said inhibitor of eIF5A is selected from an RNA interference agent targeting eIF5A mRNA, DOHH mRNA or DHS mRNA.
3. The method of claim 2 , wherein said RNA interference agent is selected from an antisense oligonucleatide, siRNA, shRNA, or a vector comprising a DNA sequence encoding said antisense oligonucleotide, siRNA, or shRNA.